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A cross-sectional survey of potential factors,
motivations, and barriers influencing
research participation and retention among
people who use drugs in the rural USA
Angela T. Hetrick1* , April M. Young2,3, Miriam R. Elman4, Sarann Bielavitz4,5, Rhonda L. Alexander2,
Morgan Brown1, Elizabeth Needham Waddell4,5, P. Todd Korthuis4,5 and Kathryn E. Lancaster1

Abstract
Background: Despite high morbidity and mortality among people who use drugs (PWUD) in rural America, most
research is conducted within urban areas. Our objective was to describe influencing factors, motivations, and
barriers to research participation and retention among rural PWUD.
Methods: We recruited 255 eligible participants from community outreach and community-based, epidemiologic
research cohorts from April to July 2019 to participate in a cross-sectional survey. Eligible participants reported opioid
or injection drug use to get high within 30 days and resided in high-needs rural counties in Oregon, Kentucky, and
Ohio. We aggregated response rankings to identify salient influences, motivations, and barriers. We estimated
prevalence ratios to assess for gender, preferred drug use, and geographic differences using log-binomial models.
Results: Most participants were male (55%) and preferred methamphetamine (36%) over heroin (35%). Participants
reported confidentiality, amount of financial compensation, and time required as primary influential factors for research
participation. Primary motivations for participation include financial compensation, free HIV/HCV testing, and
contribution to research. Changed or false participant contact information and transportation are principal barriers to
retention. Respondents who prefer methamphetamines over heroin reported being influenced by the purpose and use
of their information (PR = 1.12; 95% CI: 1.00, 1.26). Females and Oregonians (versus Appalachians) reported knowing
and wanting to help the research team as participation motivation (PR = 1.57; 95% CI: 1.09, 2.26 and PR = 2.12; 95% CI:
1.51, 2.99).
Conclusions: Beyond financial compensation, researchers should emphasize confidentiality, offer testing and linkage
with care, use several contact methods, aid transportation, and accommodate demographic differences to improve
research participation and retention among rural PWUD.
Keywords: Rural, Substance use, Recruitment, Opioid, Injection drug use, Participant retention
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Introduction
The rural United States (U.S.) is in the midst of an ongoing substance use disorder epidemic. In 2019, one in
five Americans used an illicit drug and 70,630 drug overdose deaths occurred in the U.S, of which 71% were
opioid-related [1, 2]. Further exacerbating the substance
use epidemic is the prediction of the opioid epidemic’s
“4th wave” or the rise in methamphetamine use among
people with opioid use disorders [3–6]. People who use
drugs (PWUD) such as opioids and methamphetamines
face rising rates of HCV, HIV, and other chronic health
conditions [7–9]. When rural PWUD attempt to access
treatment for these health conditions, they face transportation barriers, stigma from healthcare providers, and
a shortage of providers who offer care for substance use
disorders (SUD) and their associated harms (e.g., HCV
and HIV) [8, 10–12].
Despite high morbidity and mortality among PWUD
in rural America, most clinical research is conducted
among urban residents [13]. Results from clinical studies
may not always translate to rural communities because
of the various demographic, sociocultural, and infrastructural differences [14–17]. PWUD in rural communities may benefit from participation in research through
otherwise unavailable access to SUD knowledge, specialists, and medical facilities, the receipt of new and effective treatments and medical care, and supported linkage
to community SUD resources and programs [18, 19]. Although research studies such as clinical trials may provide valuable care and treatment to rural PWUD,
retention and recruitment remains challenging [15, 20,
21]. Those in rural communities note mistrust and fear
as contributors to low recruitment, and rural residents
have a lower likelihood of awareness of opportunities to
participate in research compared to their urban counterparts [21, 22].
Factors affecting clinical trial recruitment and retention can be categorized using the Ickovics and Mieslers
multifactorial framework: the individual, treatment regimen, patient-provider relationship, clinical setting, and
the disease [23]. There is mixed evidence for the presence of individual level differences in research enrollment and retention between genders. The National
Institute on Drug Abuse (NIDA) Treatment Clinical Trials Network (CTN) did not identify proportional differences in enrollment and retention between genders, and
willingness to participate in an HCV vaccine trial among
PWUD did not differ by gender [24–26]. However, other
studies suggest that women are underrepresented in
HCV and HIV clinical research [27], and gender differences in utilization of harm reduction services exist
among rural PWUD [28]. Further, there is some evidence to indicate that considerations for participating in
research studies differ by gender [29, 30]. An individual’s
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drug preference for methamphetamine over heroin may
also impact trust in research due to adverse effects such
as elevated paranoia and suspiciousness associated with
methamphetamine use [31]. Patient-provider relationship factors such as stigmatizing attitudes unique to certain drugs [32–34] could result in variations in the
perceived judgment by staff as a factor affecting participation in research studies, including studies irrelevant to
substance use.
Our study’s primary objective is to describe the influencing factors, motivations, and barriers of rural PWUD
in participation and retention in research studies. The
study’s secondary objective is to examine variation in influencing factors, motivations, and barriers across geographic regions, gender, and substance use to inform
retention and recruitment strategies.

Methods
Study setting

We conducted a cross-sectional survey from April to
July 2019 in rural areas of Kentucky, Ohio, and Oregon,
where each state has an established research infrastructure through the National Rural Opioid Initiative [35].
Rural study sites in Eastern Kentucky and Southeastern
Ohio are located in Appalachia, a cultural and geographical region that spans 13 states from New York to Mississippi [36]. The Oregon rural study sites in the Pacific
Northwest include both coastal and interior communities in large, sparsely populated counties. The populations in these areas of Appalachia and Oregon are
predominantly White, and an estimated 12–38% of the
population lives below the poverty line, compared to the
U.S. national average of 10.5% [37, 38]. These rural communities are at increased vulnerability for HIV and HCV
transmission due to high injection drug use rates and inadequate healthcare infrastructures [39–41].
Study design

The cross-sectional, multi-state survey was part of the
formative phase of the Peer-based Retention of People
who Use Drugs in Rural Research (PROUD-R2) study
that tests rural peers’ ability to improve study retention
(ClinicalTrials.gov identifier: NCT03885024) [42]. We
estimated that a sample size of 225 participants, or approximately 75 participants per site, would provide a saturation of responses to inform the central phase of
PROUD-R2.
Eligible participants were at least 18 years of age,
injected any drug or used opioids through non-injection
methods (such as smoking, inhaling, snorting, or swallowing) to get high within the past 30 days, and lived within
rural counties associated with each study site. We recruited participants using convenience sampling at syringe
service programs, local health departments, community-
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based settings, and through concurrent epidemiologic
studies. We obtained informed consent from all participants and provided each participant with $20 cash or a gift
card as reimbursement for survey participation. The survey was interviewer-administered in Kentucky and Oregon and self-administered in Ohio. In Ohio, trained study
staff followed an IRB-approved script to recruit and verbally determine participant eligibility as persons departed
a local, weekly syringe service program. In Kentucky, individuals who had participated in a previous study on drug
use in the study region and who had consented to be contacted about future research opportunities were contacted
by the study staff and invited to participate using an IRBapproved recruitment script. To those who were interested in participating, staff verbally administered each
question from the eligibility screening survey and recorded their responses in the survey instrument. In some
cases, individuals who were screened and/or enrolled informally told their peers about the study who then called
to express interest in participating and were screened. In
Oregon, potential participants were recruited from syringe
service programs through flyers and staff and peer referrals. Survey instruments were administered and responses
electronically recorded by research staff, as in Kentucky.
We used self-administration survey methods in Ohio to
ensure confidentiality of participant responses as data collection occurred in a shared room of a local syringe service program. In Kentucky and Ohio, we collected data
using Qualtrics software, Version June 2019 (Qualtrics,
Provo, UT). In Oregon, study data were collected using
REDCap electronic data capture tools hosted at Oregon
Health & Science University [Grant#: UL1TR002369 ][43].
Data collection

We constructed our survey based on prior literature on
clinical trial participation among PWUD and adapted
from previous assessments of vaccine trial willingness
[24, 44, 45]. Questions were adapted to ask without reference to a specific vaccine or trial product to more
broadly understand factors, motivations, and barriers to
research participation and retention among rural
PWUD. The Community Advisory Board of the Kentucky CARE2HOPE study and peer recovery support
specialists of the Oregon OR-HOPE study reviewed and
approved the survey’s final version to confirm the appropriateness of the survey.
Participants provided the following demographic information: age, gender, education, race, and ethnicity. We
assessed gender using the construct, “What is your gender?” in alignment with recommendations to use gender
as opposed to sex when reporting psychosocial or cultural factors [46]. We also asked participants about recent drug use, “Have you ever injected drugs to get
high?”, “Which drugs have you injected in the past 30
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days to get high?”, and “Which is your drug of choice for
getting high?”.
To capture each participant’s history with research
studies, we asked, “Before today, have you ever participated in a research study?” Participants who selected
“yes” were prompted to select all that apply to, “What
did the research you participated in involve?” Response
options included “in-person survey(s) or interview(s),”
“telephone survey(s),” “testing for a disease or health
condition (not including a urine drug test),” “a clinical
trial testing a new drug, treatment or device,” “follow-up
appointments for surveys and/or testing,” “financial incentive (i.e., money or gift card given for participation),”
and “other (please specify).”
We collected data on (1) influencing factors for research participation, (2) motivations for participating in
research, and (3) barriers to attend follow-up research
appointments through a series of nominal response option questions in which the participant could “select all
that apply.” To elicit factors that influenced participants’
decision to participate in a research study, we asked,
“What are some of the things that people who use drugs
in this community may consider when deciding to participate in a research study?” [15 response options]. We
inquired, “What are some of the reasons that people
who use drugs in this community may decide to participate in a research study?” [10 response options] to obtain their motivations for participation in research. To
assess barriers to retention in attending follow-up research appointments, we asked, “What do you think are
some of the challenges to getting people to come back
for follow-up appointments?” [11 response options].
Each question included an “other” response option that,
if selected, prompted participants to specify a response
not listed. Complete response options for all three questions are listed in Tables 3, 4, and 5. If a participant selected more than three responses to the above questions,
they were prompted to “Select their top 3” options by
specifying their “1st choice,” 2nd choice,” and “3rd
choice” from their previously selected responses, hereafter referred to as primary, secondary, and tertiary responses. Their remaining selected responses were
categorized as “unranked.” For participants that selected
a single response, we categorized the response as “primary.” For participants that selected only two to three
responses we categorized their responses as “top three,
unranked.” If a participant ranked only one to two responses, the remaining responses were categorized as
“unranked.”
Statistical analyses

Participant sociodemographics and drug use characteristics were summarized using descriptive statistics. We excluded participants from analyses if they were missing a
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response for one or more of the eligibility questions. To
visually represent and compare the ranking of participant responses, we used diverging stacked bar charts
[47]. We displayed survey items with the highest to lowest frequency of primary, secondary, and tertiary responses. We also included counts of selected, but
unranked, responses for each survey item.
We aggregated the survey responses into 36 binary
dependent variables to analyze the differences of influencing factors, motivations for participation, and barriers
to retention in research among subgroups of the study
population. Due to small cell sizes, we condensed the
rankings of each response into dichotomous variables
(“selected,” “not selected”) that represented a participant’s response to selecting items as essential influencing
factors, motivations, or barriers.
Of the demographic variables available, we selected
and dichotomized three variables a priori with the potential to inform future research recruitment and retention protocols. Specifically, we conducted comparisons
by gender given mixed findings from previous research
on the association between gender and reasons for research participation [29, 30]. Analyses by geographic location and type of drug use address gaps in the literature
on how these factors may impact research participation.
The latter is especially important given the evolving drug
epidemic in rural areas from one that is predominated
by opioids to one of polysubstance use involving methamphetamine [48]. We assessed differences in the
dependent variable by the independent variables of gender (male, female), region (Appalachia, Oregon), and
preferred drug of choice (heroin, methamphetamine).
We combined Kentucky and Ohio into a single “Appalachia” group for several conceptual and statistical reasons:
the stratified prevalence ratios of Kentucky and Ohio
were similar when compared to Oregon, the Kentucky
and Ohio research sites are geographically close, and
both are in the Appalachian region. Of the preferred
choice of drug options included in our survey, we compared heroin and methamphetamine as most participants selected one or the other as their ideal drug of
choice. To ensure that “preferred drug of choice”
reflected actual use, we verified that most participants
had access to their preferred drug of choice by generating cross tabulations with their preferred drug of choice
and reported substance use in the past 30 days.
We selected log-binomial regression a priori to assess
differences in site, gender, and preferred drug use for
each of the 36 selected responses. Prevalence ratios (PR)
and corresponding 95% confidence intervals (CI) were
estimated for each bivariable model. To reduce bias and
improve model precision, only survey items with at least
ten responses at each level of the binary dependent variable were modeled [49–51].
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We aggregated and analyzed data using SAS software
version 9.4 (SAS Institute Inc., Cary, NC) at Oregon
Health and Science University and the Ohio State University. Plots were developed with the “HH” package in
R version 4.0.2 (R Core Team, Vienna, Austria )[52, 53].
The Ohio State University Institutional Review Board,
University of Kentucky Institutional Review Board, and
Oregon Health and Science University Institutional Review Board approved this study.

Results
Participant characteristics

A total of 290 participants completed the survey. In Oregon and Kentucky, a total of 218 participants were
screened and completed the survey, and 34 participants
were ineligible, for reasons including not meeting drug
use eligibility criteria (n = 28), living outside of the study
location (n = 4), or missing information for all eligibility
criteria (n = 2). In Ohio, a total of 72 participants were
screened and completed the survey. Participant eligibility
was assessed verbally using a recruitment and eligibility
script, and the number of ineligible participants and reasons for ineligibility were not recorded. Furthermore,
one Ohio participant was excluded from the analyses
due to missing age and could not be confirmed to meet
study eligibility. The final analytic sample contained 255
participants and included a complete set of responses
for all independent and dependent variables.
The characteristics of the 255 participants included in
our study are shown in Table 1. Most participants were
from Kentucky (n = 105), then Oregon (n = 79),
followed by Ohio (n = 71), and the median participant
age was 37 years (IQR: (30, 45); range: (19, 72)). Most
participants identified as male (55%), white (88%), and
had at least a high school diploma/General Educational
Development (GED) (73%). One participant identified
their gender as “Transgender” and another participant
identified as “Unknown/Unsure.” We excluded these
participants from the analysis between gender differences to avoid applying unreliable findings to these subpopulations resulting from their small sample sizes.
Further, if these two individuals were described in more
detail demographically and behaviorally, they may be
identifiable in their communities, and we wish to protect
their confidentiality.
Nearly all participants had a lifetime history of
injecting drugs to get high (93%) (Table 2). Most
participants preferred either heroin or methamphetamine; both groups reported recent use (92% for heroin, 95% for methamphetamine), and both were the
most commonly injected drugs in the past 30 days
(57% and 61%, respectively). Other recently injected
drugs included fentanyl (18%), buprenorphine (18%),
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Table 1 Demographics of PWUD who completed a cross-sectional survey in rural Oregon, Ohio, and Kentucky, April–July 2019
Total study population

Oregon

Kentucky

Ohio

(n = 255)

(n = 79)

(n = 105)

(n = 71)

n

%

n

%

n

%

n

%

37

(30, 45)

34

(29, 43)

37

(30, 45)

38

(32, 45)

Age
Median (IQR)
(Range)

(19, 72)

(19, 61)

(19, 72)

(25, 66)

Gender
Female

116

45

36

46

51

49

29

41

Male

137

55

43

54

54

51

40

56

Transgender

1

0

0

0

0

0

1

1

Unknown/unsure

1

0

0

0

0

0

1

1

White

225

88

60

76

104

99

61

86

Black/African American

5

2

2

3

0

0

3

4

American Indian/Alaskan
Native

6

2

5

6

0

0

1

1

Mixed race

13

5

10

13

1

1

2

3

Other

6

2

2

3

0

0

4

6

Hispanic

14

5

11

14

1

1

2

3

Non-Hispanic

241

95

68

86

104

99

69

97

Less than high school

69

27

10

13

41

39

18

25

High school diploma or GED

106

42

36

46

40

38

30

42

Some college

59

23

29

37

19

18

11

16

Associate’s degree, trade, or technical college

16

6

3

4

4

4

9

13

Bachelor’s degree or higher

3

1

1

1

1

1

1

1

Missing

0

0

0

0

0

0

2

3

High school diploma or GED

184

73

69

87

64

61

51

74

Below high school diploma or GED

69

27

10

13

41

39

18

25

Race

Ethnicity

Education

Highest level of education

painkillers (15%), cocaine/crack (8%), methadone (3%),
and prescription anxiety drugs (3%).
Most participants had previously participated in a research
study (64%). The most commonly reported types of research
were “in-person survey or interview” (n = 152), research that
included a financial incentive (n = 120), research testing for a
disease or health condition (n = 110), and research with
follow-up appointments for a survey/testing (n = 92). Few
participants noted research experience with telephone surveys (n = 6), clinical trials (n = 5), and other (n = 6). Participants who selected “other” reported participating in a
research study that included, “drug swa(b) test,” “filling out
papers,” “Narcan,” “computer surveys,” “internet surveys,”
and one participant left their response blank.

Patterns of influencing factors in decision to participate
in research studies

The primary influencing factor for research participation
was the amount of financial compensation received in
exchange for participation (Fig. 1), followed by confidentiality of information. Other essential influencing factors
among rural PWUD were the time required to participate in the research study and privacy of the research office. The influencing factor with the least number of
ranked responses was whether the research institution
or university was well-respected. Five participants selected “other” as an influencing factor for research participation. “Other” responses included “how much [the
study] would help the community,” “whose approaching

Hetrick et al. Trials

(2021) 22:948

Page 6 of 17

Table 2 Drug use history among rural PWUD in Kentucky, Ohio, and Oregon, April 2019–July 2019
Total study population (n = 255)

Oregon (n = 79)

Kentucky (n = 105)

Ohio (n = 71)

n

%

n

%

n

%

n

%

Yes

237

93

75

95

95

90

67

94

No

18

7

4

5

10

10

4

6

Ever injected drugs to get high

Drugs injected to get high in past 30 days
Methamphetamines

155

61

61

77

70

67

24

34

Heroin

144

57

42

53

48

46

54

76

Buprenorphine

47

18

5

6

33

31

9

13

Fentanyl

47

18

14

18

10

10

23

32

Painkillers

38

15

21

27

12

11

5

7

Cocaine/crack

21

8

11

14

6

6

4

6

Othera

11

4

10

13

0

0

1

1

Methadone

8

3

5

6

2

2

1

1

Prescription anxiety drugs

8

3

6

8

1

1

1

1

Gabapentin

1

1

1

1

0

0

0

0

Kratomb

1

1

1

1

0

0

-

-

Clonidine

0

0

0

0

0

0

0

0

Synthetics

0

0

0

0

0

0

0

0

Methamphetamines

91

36

37

47

45

43

9

13

Heroin

90

35

33

42

24

23

33

47

Buprenorphine

14

6

0

0

12

11

2

3

Painkillers

13

5

2

3

11

11

0

0

Fentanyl

5

2

0

0

0

0

5

7

c

Other

3

1

3

4

0

0

0

0

Gabapentin

2

1

0

0

0

0

2

3

Methadone

1

1

0

0

1

1

0

0

Cocaine/crack

1

1

0

0

1

1

0

0

Drug of choice to get high

“Other” responses included “cannabis” (n = 9), “pot, lsd, mushrooms, acid” (n = 1) and one response was missing (n = 1)
b
Kratom was not listed as a response option in the Ohio survey
c
“Other” responses included “pot” (n = 2) and “lsd, doc, mushrooms” (n = 1)
a

them and how they are approached,” and two responses
were left blank.
In considering participation in research, Oregon respondents had a higher prevalence of selecting all influencing
factors listed compared to Appalachian respondents.
When compared to Appalachian respondents, Oregon respondents were more influenced by how much time is required for participation (PR = 1.42; 95% CI: 1.21, 1.67)
and the frequency of research appointments (Oregon
prevalence: 87%, Appalachian prevalence: 41%, PR = 2.14;
95% CI: 1.75, 2.60). Oregon respondents also had a higher
prevalence of noting schedule conflicts, such as whether
they have childcare available to attend research appointments (Oregon prevalence: 65%, Appalachian prevalence:
42%, PR = 1.54; 95% CI: 1.21, 1.95), and if their appointment times will interfere with their work schedule (PR =

1.63; 95% CI: 1.24, 2.14). Privacy of the research office (PR
= 1.32; 95% CI: 1.13, 1.53) and knowledge of why their information is being collected and what it will be used for
(PR = 1.46; 95% CI: 1.24, 1.73) were increased concerns
among Oregon compared to Appalachian respondents
(Table 3).
Compared to males (n = 137), female participants (n =
116) were more influenced to participate if they could
skip uncomfortable questions of parts of the study (PR =
1.34; 95% CI: 1.09, 1.65) and if their information would
be kept confidential (prevalence, females: 79%; males:
70%; PR = 1.15; 95% CI: 0.99, 1.32) (Table 4).
Compared to those who selected heroin (n = 90) as
their preferred drug of choice, respondents who selected
methamphetamine (n = 91) were more influenced by the
privacy of the research office (PR = 1.10; 95% CI: 0.99,
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Fig. 1 Ranked influencing factors for participating in research among PWUD in rural communities, April 2019–July 2019

1.20), knowing why their information is collected and
what it will be used for (prevalence, heroin: 59%, methamphetamine: 74%; PR = 1.12; 95% CI: 1.00, 1.26), and
the confidentiality of their information (PR = 1.07; 95%
CI: 0.99, 1.16) (Table 5).
Patterns of motivations for research participation

Financial compensation was the primary motivator for participation, followed by free diagnostic testing for infectious
diseases such as HCV and HIV, and believing in the mission
of the research and wanting to contribute (Fig. 2). “Knowing
a person on the research team and wanting to help them
out” was the least selected motivator for participation. Fifteen
participants selected “other” as a motivator for research participation, while two participants left the response blank.
“Other” responses included “it’s convenient,” “people get
tired of watching their friends die,” “people might participate
because of their families,” and “some people want to come
and talk about getting off drugs and talk about resources.”

Compared to Appalachia respondents, Oregon respondents had a higher prevalence of motivation to enroll in research if they believe in the mission of the
research and want to contribute (PR = 1.42; 95% CI:
1.18, 1.70) and to tell their story (PR = 1.37; 95% CI:
1.11, 1.70). The prevalence of noting feeling pressured
to participate by peers to share the financial incentive
(PR = 2.18; 95% CI: 1.56, 3.03) and knowing someone
on the research team and wanting to help them out (PR
= 2.12; 95% CI: 1.51, 2.99) was over two times greater
among Oregon respondents compared to Appalachian
respondents (Table 3).
Female participants were nearly twice as likely to report being motivated to participate in a research study if
they knew someone on the research team (PR = 1.81;
95% CI: 1.09, 2.26) and were marginally more motivated
to participate if a financial incentive was offered (prevalence, females: 41%, males: 32%; PR = 1.10; 95% CI: 0.99,
1.23) (Table 4).
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Table 3 Influencing factors and motivators to research participation and barriers to retention: Oregon versus Appalachia PWUD
Survey item

Oregon (n = 79)

Appalachia
(n = 176)

Prevalence
ratioa,b

95%
CI

Selected Not
Selected Not
selected
selected
Influencing factors
What the research study involves (e.g., survey, drug testing for research)c

71

8

111

65

–

–

How much time is required

65

14

102

74

1.42*

(1.21,
1.67)

How often they have to come in for visits

69

10

72

104

2.14*

(1.75,
2.60)

How far they have to travel to participate (i.e., nearby vs. out of town)c

70

9

92

84

–

–

Privacy of the research office

65

14

110

66

1.32*

(1.13,
1.53)

Why their information is being collected and what it will be used for

65

14

99

77

1.46*

(1.24,
1.73)

Whether their information will be kept confidentialc

72

7

118

58

–

–

Whether the staff doing the research is friendly and trustworthy

76

3

114

62

–

–

Whether the research institution or university is respected

44

35

78

98

1.26

(0.97,
1.63)

Whether they can skip questions of parts of the study that make them
uncomfortable

60

19

88

88

1.52*

(1.25,
1.84)

How much money they will receivec

70

9

113

63

–

–

How much the project will benefit them overallc

70

9

88

88

–

–

Whether their appointment times will interfere with their work schedule

46

33

63

113

1.63*

(1.24,
2.14)

Whether they have childcare so that they can attend their appointments

51

28

74

102

1.54*

(1.21,
1.95)

How their friends, family, or partner feels about them participating

49

30

64

112

1.71*

(1.31,
2.21)

Financial incentive (i.e., money or gift card given for participationc

79

0

134

42

–

–

They believe in the mission of the research and want to contribute

61

18

96

80

1.42*

(1.18,
1.70)

Their friends, family, or partner participates

65

14

97

79

1.49*

(1.26,
1.77)

They want to tell their story

53

26

86

90

1.37*

(1.11,
1.70)

They know someone on the research team and want to help them out

40

39

42

134

2.12*

(1.51,
2.99)

They want to learn about the topic

51

28

79

97

1.44*

(1.14,
1.81)

They would want to get free testing (for example, rapid tests for HIV
& Hepatitis C) if it was offered as part of the studyc

71

8

102

74

–

–

They would want to be linked with resources and/or follow-up testing
if it was offered as part of the study

69

10

103

73

1.49*

(1.28,
1.73)

They would want to try a new treatment if it was offered as part of
the study

68

11

105

71

1.44*

(1.24,
1.68)

Their friends, family, or partner pressures them to participate so that
they can share the financial incentive

42

37

43

133

2.18*

(1.56,
3.03)

74

5

133

43

–

–

c

Motivations

Barriers
Not being able to get in touch with participants because their contact
information changedc
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Table 3 Influencing factors and motivators to research participation and barriers to retention: Oregon versus Appalachia PWUD
(Continued)
Survey item

Oregon (n = 79)

Appalachia
(n = 176)

Prevalence
ratioa,b

95%
CI

Selected Not
Selected Not
selected
selected
Not being able to get in touch with participants because they gave false
contact information when they started the study

46

33

100

76

1.02

(0.82,
1.29)

They may have trouble getting transportation for their appointments

64

15

124

52

1.15

(0.99,
1.33)

They may have trouble being able to show up at a specific appointment timec

72

7

108

68

–

–

They may have trouble getting to their appointment because of their work
schedule

51

28

71

105

1.60*

(1.26,
2.04)

They may have trouble finding childcare so that they can go to their
appointment

53

26

74

102

1.60*

(1.26,
2.01)

They may have concerns about confidentiality and privacy

54

25

79

97

1.52*

(1.22,
1.90)

They may be afraid that the staff would judge them if they are still using drugs

41

38

76

100

1.20

(0.92,
1.58)

They may have stopped using drugs and no longer think the study is relevant
to them

47

32

74

102

1.42*

(1.10,
1.82)

They are in a drug treatment or recovery facility and are unable to be contacted 55
by research staff

24

92

84

1.33*

(1.09,
1.63)

Their friends, family, or partner may want them to stop participating

51

49

127

1.27

(0.87,
1.86)

28

Kentucky and Ohio sites were combined to represent the referent group of “Appalachia”
The level of response for each survey item was dichotomized into “selected” or “not selected” to generate prevalence ratios
c
Oregon cell sizes for “not selected” were < 10; analysis not performed
* Significant at α =0.05 level
a

b

Respondents whose preferred drug of choice was
methamphetamine had a higher prevalence of being motivated to participate in research if they would receive
free diagnostic testing (PR = 1.08; 95% CI: 0.99, 1.18)
and linkage to resources and follow-up testing as part of
the study (PR = 1.09; 95% CI: 0.99, 1.21), compared to
respondents whose preferred drug of choice was heroin
(Table 5).
Patterns of anticipated barriers for retention in follow-up
research appointments

Losing contact with participants due to changed contact information had the highest frequency of primary
responses among barriers to returning to follow-up
research appointments, followed by trouble obtaining
transportation and sharing false contact information
at their initial appointment (Fig. 3). The barrier with
the lowest number of ranked responses among respondents was that their friends, family, or partner
may want them to stop participating. Twenty participants selected “other” as a barrier for research participation, while three participants left the response
blank. Their responses included, “being under the influence of drugs,” “if they did get clean this could be
a trigger to come into the office,” “it’s not that important to them,” “they may be high and forget,”

“people are scared to be tested for disease,” “people
aren’t in stable environments and move a lot,” “people
forget about the survey,” and “can’t force people to
come in, they make their own choices.”
Reporting conflicts in returning to follow-up appointments due to work, finding childcare, and transportation
were greatest among Oregon participants compared to
Appalachian participants (PR = 1.60; 95% CI: 1.26, 2.04,
PR = 1.60; 95% CI: 1.26, 2.01, and prevalence, Oregon:
81%, Appalachian: 70%; PR = 1.15; 95% CI: 0.99, 1.33, respectively). Oregon participants also had a higher prevalence of reporting privacy and confidentiality concerns
(PR = 1.52; 95% CI: 1.22, 1.90) and becoming unreachable due to participation in a drug treatment program
(PR = 1.33; 95% CI: 1.09, 1.63). Barriers that did not differ between Appalachian and Oregon participants included not being able to get in touch with participants
because they provided false contact information and they
may be afraid that the staff would judge them if they are
still using drugs (Table 3).
Female participants were more likely to identify
trouble finding transportation (PR = 1.12; 95% CI:
0.96, 1.30) and childcare (prevalence, females: 32%,
males: 21%; PR = 1.26; 95% CI: 0.98, 1.61) as challenges to returning to follow-up research appointments (Table 4).
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Table 4 Influencing factors and motivators to research participation and barriers to retention among PWUD: gender differences
Survey item

Male (n = 137)

Female (n = 116)

Selected Not
Selected Not
selected
selected

Prevalence
ratioa,b

95% CI

Influencing factors
What the research study involves
(e.g., survey, drug testing for research)

100

37

81

35

0.98

(0.84, 1.15)

How much time is required

87

50

72

44

1.02

(0.85, 1.23)

How often they have to come in for visits

78

59

61

55

0.98

(0.78, 1.22)

How far they have to travel to participate
(i.e., nearby vs. out of town)

85

52

76

40

1.09

(0.90, 1.31)

Privacy of the research office

92

45

81

35

1.18

(0.70, 2.01)

Why their information is being collected and what it
will be used for

86

49

77

39

1.09

(0.91, 1.31)

Whether their information will be kept confidential

97

40

92

24

1.15

(0.99, 1.32)

Whether the staff doing the research is friendly and trustworthy

102

35

87

29

1.03

(0.89, 1.19)

Whether the research institution or university is respected

65

72

57

59

1.05

(0.81, 1.36)

Whether they can skip questions of parts of the study that
make them uncomfortable

70

67

77

39

1.34*

(1.09, 1.65)

How much money they will receive

99

38

82

34

1.01

(0.87, 1.18)

How much the project will benefit them overall

81

56

77

39

1.14

(0.94, 1.38)

Whether their appointment times will interfere with
their work schedule

64

73

45

71

0.84

(0.63, 1.13)

Whether they have childcare so that they can attend
their appointments

66

71

59

57

1.07

(0.83, 1.38)

How their friends, family, or partner feels about them
participating

68

69

45

71

0.79

(0.60, 1.05)

Financial incentive (i.e., money or gift card given for participation)

110

27

100

16

1.10

(0.99, 1.23)

They believe in the mission of the research and want to contribute

86

51

71

45

0.99

(0.81, 1.20)

Their friends, family, or partner participates

89

48

72

44

0.98

(0.82, 1.19)

They want to tell their story

77

60

62

54

0.96

(0.77, 1.21)

They know someone on the research team and want to
help them out

36

101

45

71

1.57*

(1.09, 2.26)

They want to learn about the topic

73

64

56

60

0.94

(0.74, 1.20)

They would want to get free testing (for example, rapid
tests for HIV & Hepatitis C) if it was offered as part of the study

93

44

79

37

1.03

(0.87, 1.22)

They would want to be linked with resources and/or follow-up
testing if it was offered as part of the study

93

44

78

38

1.02

(0.86, 1.21)

They would want to try a new treatment if it was offered as
part of the study

93

44

79

37

1.03

(0.87, 1.22)

Their friends, family, or partner pressures them to participate so
that they can share the financial incentive

50

87

35

81

0.84

(0.59, 1.20)

Not being able to get in touch with participants because
their contact information changed

111

26

94

22

1.03

(0.91, 1.16)

Not being able to get in touch with participants because they
gave false contact information when they started the study

76

61

69

47

1.11

(0.90, 1.37)

Motivations

Barriers

They may have trouble getting transportation for their appointments

97

40

89

27

1.12

(0.96, 1.30)

They may have trouble being able to show up at a specific
appointment time

94

43

85

31

1.09

(0.93, 1.28)
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Table 4 Influencing factors and motivators to research participation and barriers to retention among PWUD: gender differences
(Continued)
Survey item

Male (n = 137)

Female (n = 116)

Selected Not
Selected Not
selected
selected

Prevalence
ratioa,b

95% CI

They may have trouble getting to their appointment because
of their work schedule

66

71

55

61

1.03

(0.79, 1.33)

They may have trouble finding childcare so that they can go to their
appointment

62

75

65

51

1.26

(0.98, 1.61)

They may have concerns about confidentiality and privacy

70

67

62

54

1.08

(0.86, 1.37)

They may be afraid that the staff would judge them if they
are still using drugs

60

77

56

60

1.15

(0.88, 1.50)

They may have stopped using drugs and no longer think the
study is relevant to them

63

74

57

59

1.11

(0.86, 1.44)

They are in a drug treatment or recovery facility and are unable
to be contacted by research staff

81

56

65

51

0.98

(0.79, 1.21)

Their friends, family, or partner may want them to stop participating

38

99

39

77

1.23

(0.85, 1.79)

a

Male is the referent group
The level of response for each survey item was dichotomized into “selected” or “not selected” to generate prevalence ratios
*Significant at α = 0.05 level
b

Participant-prioritized barriers did not differ by drug
of choice (Table 5).

Discussion
We identified several themes of rural PWUD considerations in deciding to participate and remain in research
studies. The primary influencing factor and motivator
for rural PWUD to participate in research is the amount
and presence of financial compensation. Economic and
social factors of the risk environment framework are determinants of substance use [54] and promote a disproportionate burden of substance use among people living
below the federal poverty threshold [1]. A lack of assistance programs in areas where rural PWUD reside further exacerbate the economic needs of this population
[55, 56]. The weight of financial compensation in our
findings is consistent with studies of rural Kentucky
PWUD populations and others that note receipt of financial compensation as positively associated with research participation and retention [24, 57, 58]. Lower
economic status is also associated with poorer study retention; once enrolled in a longitudinal research study,
PWUD who live below the federal poverty line are more
likely to be lost to follow-up [59]. While financial compensation can be used to offset economic needs of participants and costs to participate such as travel and
childcare, additional research is required to ascertain appropriate levels of financial compensation that do not
coerce study participation among PWUD [60].
Financial need is an undercurrent relevant to other
highly noted factors. Transportation was a major perceived barrier to retention among all participants irrespective of participant region, gender, or preferred drug
use. Our findings align with previous studies that note

transportation, or distance, as a primary barrier to retention among rural community members [20]. Western
Oregon’s remote setting may increase transportation
challenges. Oregon participants were more likely to consider factors and motivations for participation related to
transportation concerns such as the frequency of research appointments and if their friend, family, or partner participates. Strategies to alleviate transportation
challenges might include travel reimbursement, financial
incentive amounts that account for transportation cost,
or mobile or outreach models that bring the research to
the participant.
Although financial incentive is the primary motivation
for research participation among rural PWUD, our study
supports other findings that motivations are multidimensional beyond monetary gains such as believing in
the mission of the research and seeking linkage to care
and other resources [57]. A lack of income paired with
scarce medical care in rural locations may also explain
the motivations noted by most rural PWUD to participate if linkage with resources and free testing are offered
as part of the study. In the U.S., cost or lack of reimbursement by insurance companies and uncertainty
about where to receive HIV care are reported as the primary barriers to HIV testing [61]. Due to a lack of
healthcare assistance programs and primary care providers in rural communities, and stigma in healthcare
settings, PWUD may prefer to access HCV and HIV
screening offered by research studies [8, 55].
Privacy, confidentiality, and interaction quality with
research staff are crucial influencing factors for PWUD
in deciding to participate in research, likely due to
stigma and the legal, employment, and inter-personal
relationship consequences of substance use. Oregon
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Table 5 Influencing factors and motivators to research participation and barriers to retention: drug of choice differences, heroin vs.
methamphetamine
Survey item

Heroin (n = 90)

Methamphetamine
(n = 91)

Prevalence
ratioa,b

95% CI

Selected not
selected

selected not
selected

What the research study involves
(e.g., survey, drug testing for research)

69

21

68

23

0.96

(0.86, 1.06)

How much time is required

67

23

How often they have to come in for visits

57

33

58

33

0.91

(0.79, 1.03)

56

35

0.90

(0.78, 1.05)

How far they have to travel to participate
(i.e., nearby vs. out of town)

58

32

67

24

1.01

(0.90, 1.13)

Privacy of the research office

58

32

73

18

1.10

(0.99, 1.20)

Why their information is being collected and
what it will be used for

53

37

67

24

1.12*

(1.00, 1.26)

Influencing factors

Whether their information will be kept confidential

63

27

80

11

1.07

(0.99, 1.16)

Whether the staff doing the research is friendly and trustworthyc

62

28

82

9

–

–

Whether the research institution or university is respected

39

51

51

40

1.25*

(1.08, 1.43)

Whether they can skip questions of parts of the study
that make them uncomfortable

51

39

61

30

1.04

(0.91, 1.19)

How much money they will receive

64

26

75

16

1.01

(0.92, 1.11)

How much the project will benefit them overall

58

32

68

23

0.93

(0.82, 1.05)

Whether their appointment times will interfere with
their work schedule

37

53

42

49

1.07

(0.88, 1.30)

Whether they have childcare so that they can attend
their appointments

41

49

51

40

1.08

(0.91, 1.28)

How their friends, family, or partner feels about
them participating

38

52

46

45

1.09

(0.90, 1.31)

Financial incentive (i.e., money or gift card given
for participation

79

11

81

10

0.97

(0.91, 1.04)

They believe in the mission of the research and want
to contribute

61

29

64

27

0.93

(0.82, 1.06)

Their friends, family, or partner participates

63

27

67

24

0.93

(0.82, 1.04)

Motivations

They want to tell their story

49

41

54

37

1.03

(0.88, 1.20)

They know someone on the research team and want to
help them out

27

63

37

54

1.00

(0.79, 1.28)

They want to learn about the topic

43

47

57

34

1.05

(0.90, 1.23)

They would want to get free testing (for example, rapid tests
for HIV & Hepatitis C) if it was offered as part of the study

55

35

78

13

1.08

(0.99, 1.18)

They would want to be linked with resources and/or
follow-up testing if it was offered as part of the study

55

35

73

18

1.09

(0.99, 1.21)

They would want to try a new treatment if it was offered as
part of the study

59

31

76

15

1.03

(0.93, 1.13)

Their friends, family, or partner pressures them to participate
so that they can share the financial incentive

34

56

32

59

0.88

(0.69, 1.13)

Not being able to get in touch with participants because
their contact information changed

72

18

80

11

1.00

(0.93, 1.08)

Not being able to get in touch with participants because
they gave false contact information when they started the study

51

39

61

30

0.99

(0.87, 1.14)

Barriers
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Table 5 Influencing factors and motivators to research participation and barriers to retention: drug of choice differences, heroin vs.
methamphetamine (Continued)
Survey item

Heroin (n = 90)

Methamphetamine
(n = 91)

Prevalence
ratioa,b

95% CI

Selected not
selected

selected not
selected

They may have trouble getting transportation for their appointments

68

22

71

20

0.99

(0.89, 1.09)

They may have trouble being able to show up at a specific
appointment time

62

28

72

19

1.05

(0.95, 1.16)

They may have trouble getting to their appointment because
of their work schedule

44

46

46

45

1.04

(0.89, 1.21)

They may have trouble finding childcare so that they can go to their
appointment

47

43

49

42

0.94

(0.79, 1.12)

They may have concerns about confidentiality and privacy

43

47

60

31

1.09

(0.95, 1.26)

They may be afraid that the staff would judge them if they are
still using drugs

38

52

48

43

1.09

(0.91, 1.31)

They may have stopped using drugs and no longer think the
study is relevant to them

40

50

56

35

1.01

(0.86, 1.19)

They are in a drug treatment or recovery facility and are unable to be
contacted by research staff

49

41

60

31

1.09

(0.96, 1.25)

Their friends, family, or partner may want them to stop participating

29

61

28

63

0.94

(0.71, 1.24)

a

Heroin as the preferred drug of choice is the referent group
b
The level of response for each survey item was dichotomized into “selected” or “not selected” to generate prevalence ratios
c
Cell sizes for “not selected” were < 10; analysis not performed
* Significant at α = 0.05 level

respondents were more likely to be motivated to participate in research if they knew someone on the research
staff. This finding may be related to the design of Oregon’s concurrent study (i.e., the Oregon HIV/HCV and
Opioid Prevention and Engagement, or OR-HOPE)
which employs peer recovery support specialists as study
staff members [62]. While we found that most factors
among rural PWUD did not differ between males and
females, aligning with the findings of an analysis of 24
NIDA CTN trials [26], we found a notable difference in
the importance of privacy between genders. Females reported an increased likelihood of indicating if their information would be kept confidential and whether they
can skip questions that make them uncomfortable as important for participation. Female PWUD participants
might be more concerned with privacy due to concerns
of their reputation [30] or losing custody of their children if their drug use became publicly known [55] or
due to anticipated distress around certain topics related
to past trauma. Studies that recruit primarily rural, female PWUD should highlight confidentiality protections
when obtaining informed consent and reiterate these
protections throughout surveys, questionnaires, and
other data collection items to encourage participation
and improve comfort. In accordance with standards for
best practice in research with vulnerable populations
[63, 64], behavioral research studies can further support
female rural PWUD by providing the opportunity to opt
out of questions that make them uncomfortable.

Changing of participants’ contact information was a
primary perceived barrier to returning to follow-up appointments and did not differ between participant region, gender, or preferred drug use. Our findings align
with previous studies that note successfully contacting
participants as a barrier to retention among rural community members and PWUD [65]. Obtaining information from participants about contact information of
others (family, friends, etc.) who know how to reach
them in case they cannot be contacted may improve retention [20]. The challenge of losing contact with participants may be alleviated by providing phone cards or
other forms of contact reimbursement.
Participants who reported methamphetamine as their
drug of choice to get high, as compared to those who selected heroin, had a higher prevalence of considering factors central to privacy and confidentiality. While not all of
these factors met the threshold for statistical significance
(α = 0.05), the positive measure of association speaks to a
theme of distrust and privacy concerns present among
those who prefer methamphetamine use. These findings
align with a community-based study in Vancouver,
Canada, that found those who use methamphetamine reported greater suspiciousness and paranoia compared to
those who use opioids [31]. Methamphetamine-associated
paranoia may magnify the general distrust of healthcare
systems where PWUD frequently experience stigma [66,
67] and may exacerbate skepticism about the transparency
of research which is already elevated among rural
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Fig. 2 Ranked motivators for joining a research study among PWUD in rural communities, April 2019–July 2019

residents [68]. Research enrolling people who use methamphetamines in rural communities should tailor recruitment and retention strategies to emphasize confidentiality
and privacy.
Our findings should be interpreted in light of several potential limitations. First, though our sample was drawn
from U.S. rural communities in three states, findings may
not be generalizable to rural communities outside of Appalachia and southwestern Oregon and may not be representative of all PWUD in the study communities due to
our use of convenience sampling for data collection.
Demographic characteristics of our sample align with
those of previous studies of rural PWUD in the regions included in our study (i.e., mostly male, white, low education
level, and age between 25 and 45 years [28, 69–72]); however, because county-level demographic information for
PWUD in the study areas are not publicly available, we
cannot fully assess the generalizability of our findings to
rural PWUD in these locations. Second, the numerous response options provide crucial descriptive information on
improving clinical trial recruitment and retention in rural
areas but are likely correlated. Future work with large
population-based samples will be needed for testing multiple hypotheses of multilevel factors. Still, our study
found differences in factors for participation and retention
between geographic locations and types of preferred drug

use. The cross-sectional design of our study is a limitation
in regard to capturing the challenges of enrollment and
retention over time. We recommend that future longitudinal clinical research studies explore enrolled participants’ influencing factors and motivations for
participation. Study staff should collect data on the reasons rural PWUD participants miss follow-up
appointments among participants who are not lost to
follow-up. Another limitation is the difference in administration methods between the three sites. The selfadministered survey among Ohio respondents likely contributed to a lower selection of survey item responses. We
believe the lower selection of responses biased the prevalence ratio comparisons between Oregon and Appalachia
participants up and away from the null prevalence ratio
value (i.e., 1.0). However, previous studies have demonstrated no difference in responses between interviewerand self-administered surveys [73, 74]. Based on our results, further research is needed to determine if a difference in modes of survey administration is present among
PWUD populations. A further limitation is that our results may differ by recency and duration of drug use; however, the need to reduce respondent burden precluded our
ability to examine these variables of interest. Finally, participants were recruited in locations where epidemiological studies had already been recruiting rural PWUD;
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Fig. 3 Ranked barriers to returning to follow-up appointments among PWUD in rural communities, April 2019–July 2019

nearly two thirds of participants (64% overall, ranging
from 42% in Ohio to 75% in Kentucky) reported previously participating in a research study. Therefore, our results may not adequately capture the perspectives of rural
PWUD less familiar with or interested in research, which
may differ. However, because our participants are more familiar with research, the reported factors may have been
less hypothetical than with research naïve or adverse
PWUD.

influencing factors, motivations, and barriers to enhance participation and retention among rural PWUD.
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